Regorafenib combined with programmed death inhibitor after initial treatment failure in unresectable hepatocellular carcinoma

doi:10.4251/wjgo.123385

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 11

This Article

(5)

(7)

(0)

(335)

Peer-Review Report of This Article

Supplementary Materials of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123385
Published online Nov 15, 2026. doi: 10.4251/wjgo.123385

Full Size Figure Download Figure

Figure 3 Comparison of second-line treatment strategies. A: Overall survival; B: Progression-free survival in regorafenib combined with programmed cell death1 inhibitors group vs regorafenib monotherapy group. RP: Regorafenib combined with programmed cell death1 inhibitors; R: Regorafenib monotherapy.

Citation: Ma F, Zheng LY, Song DJ, Zhao ZW, Cao F, Hao WY, Qiu JQ, Lu D, Zheng JP. Regorafenib combined with programmed death inhibitor after initial treatment failure in unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(11): 123385
URL: https://www.wjgnet.com/1948-5204/full/v18/i11/123385.htm
DOI: https://dx.doi.org/10.4251/wjgo.123385

Ma F, Zheng LY, Song DJ, Zhao ZW, Cao F, Hao WY, Qiu JQ, Lu D, Zheng JP. Regorafenib combined with programmed death inhibitor after initial treatment failure in unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(11): 123385 [DOI: 10.4251/wjgo.123385]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.